Piper Sandler Maintains Overweight on Solventum, Lowers Price Target to $92

Benzinga Newsdesk www.benzinga.com Negative 59.8%

Neg 59.8% Neu 0% Pos 0%

Piper Sandler analyst Jason Bednar maintains Solventum (NYSE:SOLV) with a Overweight and lowers the price target from $98 to $92.